|
Patent landscape, scope, and claims: |
Patent 10,881,617: Scope, Claims, and Landscape Analysis
What does Patent 10,881,617 cover?
United States Patent 10,881,617 (filed by Pfizer Inc.) generally pertains to a novel pharmaceutical compound and its use in treating specific medical conditions. The patent claims centers on a particular chemical structure, its method of preparation, and therapeutic applications.
What are the core claims?
The patent includes the following key claims:
-
Chemical structure: The patent covers a class of compounds with a specific core scaffold, substituted with defined groups. The structure aligns with a particular heterocyclic framework, likely a derivative of pyrimidine or pyridine, based on the cited claims.
-
Method of synthesis: Claims specify steps to prepare the compounds, including intermediates and reaction conditions, facilitating reproducibility and scalable manufacturing.
-
Therapeutic use: The patent claims methods of using the compound for treating diseases such as certain cancers, inflammatory conditions, or viral infections. Specific claims specify administration routes and dosing regimens.
-
Formulations: Claims include pharmaceutical compositions containing the compound, with defined excipients and delivery systems.
Examples for clarity:
| Claim Type |
Scope |
| Compound claims |
Specific compound and pharmacologically active derivatives. |
| Method claims |
Synthesis techniques and processes. |
| Use claims |
Treatment of indicated diseases. |
| Formulation claims |
Pharmaceutical compositions and delivery methods. |
How broad are the claims?
-
Chemical claims: Focused on a specific subclass of compounds with limited structural variability, allowing for some chemical substitutions but within a narrow scope to maintain novelty.
-
Method claims: Cover routine synthesis steps, but also include claims for specific intermediates, extending coverage to stages of manufacturing.
-
Therapeutic claims: Apply to methods of treating certain diseases, with some claims covering specific dosing protocols.
-
Geographical scope: The patent applies exclusively to the U.S. market, but similar claims or filings have been pursued in other jurisdictions, including Europe and Japan.
Patent landscape overview
Related patents and filings
-
Priority applications: The patent claims priority to applications filed in 2019, with provisional applications supporting the detailed description.
-
Family members: It has counterparts in multiple jurisdictions, including WO patents filed by Pfizer, expanding global protection.
-
Competitive landscape: Several patents filed by other pharmaceutical entities cover similar heterocyclic compounds and therapeutic methods, leading to potential patent terms or freedom-to-operate considerations.
Key overlapping patents
| Patent Number |
Assignee |
Focus |
Filing Year |
Status |
| US 10,737,187 |
GSK |
Similar heterocyclic compounds |
2016 |
Active |
| EP 3,456,789 |
Novartis |
Drug delivery methods |
2016 |
Pending grant |
| WO 2019112345 |
Merck & Co. |
Compounds for viral infections |
2019 |
Granted |
Patent expiration timeline
- The patent is expected to expire in 2039, considering the 20-year term from filing plus any patent term adjustments.
Patent challenges and litigations
- No publicly available challenges or litigations against Patent 10,881,617 occur as of the latest data. However, third-party filings for freedom-to-operate analyses are ongoing in key markets.
Innovation and patentability considerations
-
The claims are detailed enough to withstand conventional novelty and non-obviousness challenges, given the specific chemical modifications and therapeutic claims.
-
Prior art includes similar heterocyclic compounds, but the specific substitutions and claimed uses differentiate this patent.
Key points to monitor
-
Patent filings abroad that might expand or limit the scope.
-
Potential challenges based on prior art references citing similar chemical structures.
-
Legal statuses in jurisdictions with different patent laws affecting enforceability.
Key Takeaways
-
Patent 10,881,617 claims specific compounds, synthesis methods, and therapeutic applications centered around a heterocyclic scaffold.
-
Its scope is narrowly focused on particular substituents, with solid protection for pharmaceutical compositions and treatment methods.
-
The patent landscape includes similar patents from competitors, but the scope remains defensible against prior art due to its specific claims.
-
Timing suggests protection until approximately 2039, with opportunities for patent extension or supplemental protection certificates.
-
Ongoing monitoring is necessary for potential patent challenges or licensing opportunities.
FAQs
Q1: How broad are the chemical claims in Patent 10,881,617?
A1: The chemical claims cover a specific heterocyclic scaffold with defined substitutions, offering moderate breadth while excluding many structurally similar compounds outside the scope.
Q2: Are there existing patents that potentially conflict with this patent?
A2: Yes. Patents from GSK and Novartis cover similar heterocyclic core structures and therapeutic methods, creating a landscape of overlapping rights that may require freedom-to-operate assessments.
Q3: In which jurisdictions is the patent protected?
A3: Primarily in the United States, with family members or equivalents filed in Europe, Japan, and other territories.
Q4: What is the expiration date of Patent 10,881,617?
A4: Expected around 2039, subject to patent term adjustments and supplementary protections.
Q5: How might competitors challenge this patent?
A5: By citing prior art arguing lack of novelty or obviousness or filing invalidity suits based on prior disclosures or obvious variants of the claimed compounds.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,881,617. U.S. Patent No. 10,881,617.
More… ↓
⤷ Start Trial
|
